Clinical trial
Quetiapine Treatment for Symptoms Associated With Borderline Personality…
NCT00122070 · University of Medicine and Dentistry of New Jersey, Other · Completed
Key facts
| NCT number | NCT00122070 |
|---|---|
| Title | Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder |
| Official title | Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder |
| Lead sponsor | University of Medicine and Dentistry of New Jersey, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Borderline Personality Disorder |
| Intervention type | Drug |
| Interventions | Quetiapine Fumarate |
| Enrollment | 15 |
| Start date | May 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | May 1, 2008 |
| First posted | Jul 21, 2005 |
| Last update posted | Jun 10, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: